Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Trident Lifeline Ltd. Share Price
Day's Range
Day's Range
Low
₹
High
₹
Price Summary
| Previous Close | ₹244.40 |
|---|---|
| Day's Range | ₹244.25 - ₹249.00 |
| Open | ₹249.00 |
| 52 Week Range | ₹229.95 - ₹328.00 |
| Volume | 34,800 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 85.05 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 15.61 |
| TTM EPS (₹) | 15.96 |
| P/E Ratio | 25.16 |
| Book Value(₹) | 3.20 |
| PAT Margin (%) | 12.07 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 19.17 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 869.65 | 165.09 |
| Expenses | N/A | N/A |
| PBT | 136.15 | 39.48 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 104.95 | 30.28 |
About Trident Lifeline Ltd.
| Founded | 2014 |
|---|---|
| Managing Director | Shravan Harikrishna Patel |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,30,908.56 | 1,787.20 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,73,929.70 | 6,499.35 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,47,181.46 | 4,285.05 | 3,102.00 - 3,102.00 |
| Apollo Hospitals Enterprise Ltd. | 1,16,456.95 | 8,107.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,12,352.94 | 1,378.90 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,09,765.03 | 1,080.20 | 835.50 - 835.50 |
| Dr. Reddy's Laboratories Ltd. | 1,07,608.15 | 1,276.40 | 1,148.40 - 1,148.40 |
| Lupin Ltd. | 1,03,326.21 | 2,252.90 | 1,836.80 - 1,836.80 |
| Mankind Pharma Ltd. | 95,809.39 | 2,300.45 | 1,909.70 - 1,909.70 |
| Max Healthcare Institute Ltd. | 91,343.80 | 949.55 | 903.00 - 903.00 |
No Records Found
Latest News
Trident Lifeline informs about updates
Trident Lifeline informs about trading window closure
Hindustan Bio Sciences informs about newspaper publication
Gland Pharma informs about allotment of equity shares
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; Gland Pharma has informed that the ESOP Compensation Committee of the Board of Directors of the Company in its meeting held on June 02, 2026, has allotted 2,03,259 Equity shares of Re 1 each of the Company, fully paid up, to 77 employee(s) on exercise of their Stock Options pursuant to Gland Pharma Employee Stock Options Scheme, 2025. Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to Rs 164,959,682 comprising 164,959,682 Equity shares of face value Re 1 each. Further, it has enclosed the details as required under Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.
The above information is a part of company’s filings submitted to BSE.
Shelter Pharma informs about receipt of renewal manufacturing licence
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Trident Lifeline Ltd. is ₹244.40 as of 2026-06-02.
The market capitalisation of Trident Lifeline Ltd. is ₹297.31 as of 2026-06-01.
The 1-year return of Trident Lifeline Ltd. is -32.50% as of 2025-05-29.
The P/E ratio of Trident Lifeline Ltd. is 25.16 as of 2026-06-02.
The 52-week high and low of Trident Lifeline Ltd. are ₹328.00 and ₹229.95, respectively, as of 2026-06-02.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
